Casdin Capital, LLC Bluebird Bio, Inc. Transaction History

Casdin Capital, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$16.59 - $33.89 $15.2 Million - $31 Million	-915,000 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$34.44 - $43.75 $6.54 Million - $8.31 Million	-190,000 Reduced 17.19%	915,000 $49.4 Million
Q1 2020 May 15, 2020	BUY	$26.16 - $63.5 $3.53 Million - $8.57 Million	135,000 Added 13.92%	1,105,000 $50.8 Million
Q4 2019 Feb 14, 2020	BUY	$46.96 - $61.67 $16.8 Million - $22 Million	357,500 Added 58.37%	970,000 $85.1 Million
Q3 2019 Nov 12, 2019	BUY	$59.47 - $93.1 $14.3 Million - $22.3 Million	240,000 Added 64.43%	612,500 $56.2 Billion
Q2 2019 Aug 13, 2019	BUY	$75.84 - $105.21 $1.14 Million - $1.58 Million	15,000 Added 4.2%	372,500 $0
Q1 2019 May 15, 2019	BUY	$64.44 - $104.11 $1.77 Million - $2.86 Million	27,500 Added 8.33%	357,500 $56.2 Million
Q4 2018 Feb 13, 2019	BUY	$59.1 - $93.26 $4.26 Million - $6.71 Million	72,000 Added 27.91%	330,000 $32.7 Million
Q3 2018 Nov 14, 2018	BUY	$88.86 - $117.49 $5.15 Million - $6.81 Million	58,000 Added 29.0%	258,000 $37.7 Million
Q2 2018 Aug 14, 2018	BUY	$99.64 - $127.59 $5.48 Million - $7.02 Million	55,000 Added 37.93%	200,000 $31.4 Million
Q3 2017 Nov 14, 2017	BUY	$57.74 - $91.42 $8.37 Million - $13.3 Million	145,000	145,000 $19.9 Million

150

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $649M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Casdin Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Casdin Capital, LLC with notifications on news.